资源描述
2009 1210 2024 06 03 IO+ADC PD-1+TROP2 ADC NSCLC 2014 Keytruda Opdivo PD-1 IO 20 400 IO cHL PD-1/L1 ORR 10-30%PD-1/L1 IO 5-10 IO ADC ADC IO Nectin-4 ADC Padcev la/mUC FDA TROP2 ADC CLDN18.2 ADC EGFRHER3 ADC HER2 ADC B7H3 ADC TF ADC PD-1/L1 1 IO+ADC 5-10 2 IO IO+IO+ADC 100-200%3 ADC IO+ADC 2024 ASCO/SKB264 Dato-DXd SG PD-1/L1 NSCLC TROP2 ADC+PD-1 NSCLC ORR PFS PD-L1 TPS 50%TROP2 ADC+PD-1 NSCLC III NSCLC S0360520120002 S0360524020002%()475 0.06()61,005.90 6.92()50,433.73 7.30%1M 6M 12M-3.8%-16.9%-18.1%-3.1%-19.3%-12.4%IO+ADC PD-1+EGFR ADC 2024-05-30 IO+ADC SKB264+K III 2023-06-08 IO+ADC 2023-04-10-27%-16%-5%6%23/06 23/08 23/10 24/01 24/03 24/052023-06-012024-05-31 300 2009 1210 2 TROP2 ADC.4 TROP2 ADC+PD-1/L1 NSCLC.5 PD-1/L1 NSCLC.5 TROP2 ADC+PD-1/L1 NSCLC.7 1 SKB264+PD-L1 Q2W ORR 77.6%.7 2 Dato-Dxd+K PFS 11.1.7 3 SG+K PD-L1 ORR 67%.8 NSCLC.9 ZXEVuNqNnOmNrPpMnQsNnMbRdNbRoMqQmOrNkPnNoQiNmMmQaQoOyRwMoOoOMYoNrQ 2009 1210 3 1 TROP2.4 2 TROP2 ADC.4 3 TROP2 ADC+IO NSCLC.5 4 NSCLC.5 5 PD-1 NSCLC.6 6 OptiTROP-Lung01 1B.7 7 TROPION-Lung02.8 8 EVOKE-02.9 9 TROP2 ADC+PD-1/L1 NSCLC.9 2009 1210 4 TROP2 ADC 2 TROP2 2 TACSTD2 88.7%80%71%64%-75%TROP2 1 TROP2 Shutan Liao et al.,Recent advances in Trop 2 targeted therapy for solid tumors Trodelvy/Dato-Dxd/SKB264/MK2870 2 TROP2 ADC HS-20105 I/II Dato-DXd/IBI130 I/II SKB264/MK2870/LCB84/LCB I/II ESG401/III MHB036C I/II SHR-A1921 III BAT8003/Insud Pharma I 9MW2921 I/II DAC-002/I BAT8008 I/II DXC1002 I BIO-106 I/II FDA018 I BL-M02D1 I/II FZ-AD004 I DB-1305 BioNTech/I/II JSKN-016 I GQ1010 Pyramid/I/II OBI-992/TROP2 ADC PD-1/L1/TROP ADC+PD-1/L1 NSCLC III ASCO NSCLC MbWVH60H0Ih9dBL8qd+6KJDzSda0ryHb0G1WUCrSdD6/7UrXyx5VNrB7dEcGNY0l 2009 1210 5 3 TROP2 ADC+IO NSCLC vs MK-2870-007 1L PD-L1 TPS 50%III SKB264+K vs K OS 614 2023-12 MK-2870-019 Stage IIIIIB(N2)III SKB264+K vs K DFS 780 2024-04 MK-2870-023 1L III SKB264+K vs K OS 851 2024-07 SKB264-II-05 II SKB264+KL-A167 ORR AE 110 2022-05 SKB264-II-04 1L II SKB264+K ORR DLT 296 2023-04 BL-B01D1-SI-B003-201-01 2L II BL-B01D1+SI-B003 ORR RP2D 121 2024-01 AVANZAR 1L III Dato-Dxd+vs/K PFS OS 1280 2022-12 TROPION-Lung07 1L PD-L1 TPS50%III Dato-Dxd+K vs+K PFS OS 975 2023-01 TROPION-Lung08 1L PD-L1 TPS 50%III Dato-Dxd+K vs K PFS OS 740 2022-03 TROPION-Lung10 1L PD-L1 TC 50%III Dato-Dxd+rilvegostomig vs K PFS OS 675 2024-04 TROPION-Lung04 1L/2L I Dato-Dxd+/rilvegostomig DLT 321 2021-02 TROPION-Lung02 I Dato-Dxd+K DLT TEAE 145 2020-09 EVOKE-03 1L PD-L1 TPS 50%III SG+K vs K PFS OS 614 2023-02 EVOKE-02 1L II SG+K ORR DLT 193 2022-05 HUDSON 2L II DS-8201+ORR 531 2017-12 DS8201-A-U106 HER2 I DS-8201+K DLT ORR 115 2020-02 DL03 HER2 I DS-8201+K/volrustomig AE SAE 168 2021-03 SHR-A1811-II-203 2L I/II SHR-A1811+ORR DLT 324 2022-09 CIBI126A201 1L CEACAM5 II IBI126+ORR 130 2023-05 RC108-C003 2L EGFR I/II RC108+ORR DLT 106 2023-09 BA3011-002 2L II BA3011+PD-1 ORR AE 240 2021-03 ClinicalTrials.gov TROP2 ADC+PD-1/L1 NSCLC PD-1/L1 NSCLC EGFR KRAS ROS1 BRAF HER2 RET NSCLC NSCLC NSCLC 4 NSCLC I NSCLC PS=0-1 1+2+3 4 PD-L1 TC 50%IC 10%5 K PD-L1 TPS 50%PD-L1 TPS 1%-49%2A 2009 1210 6 6+/PS=0-1 1 2 3 PD-L1 TC 50%IC 10%4 K PD-L1 TPS 50%PD-L1 TPS 1%-49%2A 5/+/6+/7+8+CSCO 2023 PD-1/L1 PD-L1 NSCLC KEYNOTE-024 PD-L1 TPS 50%K ORR 44.8%vs 27.8%PFS 10.3 vs 6.0 HR 0.50 OS 26.3 vs 13.4 HR 0.63 IMpower110 PD-L1 TC 50%IC 10%NSCLC ORR 38.3%vs 28.6%PFS 8.1 vs 5.0 HR 0.63 OS 20.2 vs 13.1 HR 0.59 PD-(L)1 PD-L1 NSCLC OS PFS 5 PD-1 NSCLC KEYNOTE-189 CAMEL KEYNOTE-407 CameL-sq vs K+vs+vs K+/vs+vs ORR 48.3%vs 19.9%55.1%vs 32.9%62.6%vs 38.4%64.8%vs 36.7%TPS1%50%62.1%vs 25.7%70.0%vs 45.0%59.1%vs 37.3%1-49%50.0%vs 20.7%58.3%vs 38.1%TPS1%33.1%vs 14.3%38.8%vs 20.3%67.4%vs 41.4%PFS 9.0 vs 4.9 HR 0.49 11.0 vs 6.5 HR 0.55 8.0 vs 5.1 HR 0.57 8.5 vs 4.9 HR 0.37 TPS1%50%11.1 vs 4.8 HR 0.35 21.0 vs 5.5 HR 0.42 8.2 vs 4.6 HR 0.50 1-49%9.4 vs 4.9 HR 0.53 11.3 vs 6.8 HR 0.59 TPS1%6.2 vs 5.1 HR 0.67 7.0 vs 5.6 HR 0.75 6.3 vs 5.9 HR 0.67 OS 22.0 vs 10.6 HR 0.56 27.1 vs 19.8 HR 0.72 17.1 vs 11.6 HR 0.71 27.4 vs 15.5 HR 0.57 TPS1%50%27.7 vs 10.1 HR 0.59 NR vs 19.6 HR 0.68 18.9 vs 12.8 HR 0.67 NR vs 20.1 HR 0.47 1-49%21.8 vs 12.1 HR 0.66 29.5 vs 24.5 HR 0.76 TPS1%17.2 vs 10.2 HR 0.51 19.0 vs 16.5 HR 0.84 15.0 vs 11.0 HR 0.79 19.8 vs 14.4 HR 0.73 D.Rodrguez-Abreu et al.,Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC:protocol-specified final analysis from KEYNOTE-189 Caicun Zhou et al.,Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC:Extended Follow-Up of CameL Phase 3 Trial Luis Paz-Ares et al.,A Randomized,Placebo-Controlled Trial of pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC:Protocol Specified Final Analysis of KEYNOTE-407 C Zhou et al.,First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer:Updated overall survival results from the phase III CameL-sq trial Shengxiang Ren et al.,Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC(CameL-Sq):A Phase 3 Trial 2009 1210 7 TROP2 ADC+PD-1/L1 NSCLC 1 SKB264+PD-L1 Q2W ORR 77.6%2024 ASCO SKB264 KL-A167 PD-L1 NSCLC II OptiTROP-Lung01 NCT05351788 NSCLC SKB264 5 mg/kg Q3W+KL-A167 1200mg Q3W 1A SKB264 5 mg/kg Q2W+KL-A167 900 mg Q2W 1B 2024 1 2 1A 1B 40 63 IHC 22C3 pharmDx PD-L1 1%1%-49%50%30.0%/33.3%32.5%/30.2%37.5%/36.5%1A/1B 3 TRAEs 30.0%/30.2%5.0%/17.5%5.0%/15.9%5.0%/6.3%7.5%/0 1B 1 SKB264 1A 1B 14.0 6.9 1)1A ORR 48.6%18/37 2 DCR 94.6%PFS 15.4 95%CI 6.7 NE 6 PFS 69.2%2)1B ORR 77.6%45/58 5 DCR 100%PFS 6 PFS 84.6%6 OptiTROP-Lung01 1B 2024 ASCO SKB264 Q2W K K PD-L1 TPS 50%NSCLC III NCT06170788 2 Dato-Dxd+K PFS 11.1 2024 ASCO I TROPION-Lung02 NCT04526691 Dato-DXd+K NSCLC 6 Dato-DXd 4 6mg/kg K 200mg K+75mg/m2 AUC 5 Q3W 2009 1210 8 2023 10 31 45%20%6.6 5.8 TEAE 57%33%40%46%1-2 57%76%3 TEAE 38%44%TEAE 29%39%Dato-DXd TEAE 2%9%TEAE ORR 52%DCR 88%PFS 11.1 DoR PD-L1 50%50%76 37 39 20 5 15 PD-L1 Dato-Dxd 7 TROPION-Lung02 2024 ASCO 3 SG+K PD-L1 ORR 67%EVOKE-02 NCT05186974 II Sacituzumab govitecan SG+K mNSCLC 2024 ASCO EVOKE-02 A 11.3 EVOKE-02 A mNSCLC PD-L1 TPS 50%21 1 8 10 mg/kg SG 1 200 mg K 2023 12 1 A 30 ORR 67%67%67%PFS 13.1 13.1 DOR n=30 3(TEAE)3 TEAE 67%40%10%3 TEAE 2009 1210 9 17%10%10%17%TEAE 1 3%8 EVOKE-02 2024 ASCO NSCLC SKB264 Dato-DXd SG PD-1/L1 TROP2 ADC+PD-1 NSCLC ORR PFS PD-L1 TPS 50%TROP2 ADC+PD-1 NSCLC III NSCLC 9 TROP2 ADC+PD-1/L1 NSCLC ASCO 2024 WCLC 2023 2009 1210 10 2020 2020 2020 2020 2020 2020 2023 2021 2022 2022 2022 2023 2023 2024 2009 1210 11 010-63214682 010-63214682 010-63214682 010-63214682 010-63214682 010-66500808 010-66500821 010-63214682 0755-82828570 0755-83715428 0755-82756804 0755-82871425 021-20572536 021-20572555 021-20572257-2552 021-20572506 021-20572585 021-20572509 021-20572548 021-20572573 0755-82756805 021-20572559 021-20572559 0755-82756805 021-20572559 玙 021-25072549 2009 1210 12 A 300 500/6 20%6 10%20%6-10%10%6 10%20%3-6 5%3-6-5%5%3-6 5%26 C 3A 1061 A 19 33 12 100033 518034 200120 010-66500801 0755-82027731 021-20572500 010-66500900 0755-82828562 021-20572522
展开阅读全文